Targovax ASA: Second quarter and first half year 2018 results
Oslo, Norway, 23 August 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, today announces its second quarter and first half year 2018 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET (details below).HIGHLIGHTS FOR THE SECOND QUARTER AND FIRST HALF YEAR 2018 · In January, Targovax announced that ONCOS-102 generated immune activation at both the systemic and lesional levels in checkpoint inhibitor (CPI) refractory melanoma in four out of the first